Garg PK, Singh SK, Prakash G, Jakhetiya A, Pandey D. Role of positron emission tomography-computed tomography in non-small cell lung cancer. World J Methodol 2016; 6(1): 105-111 [PMID: 27018223 DOI: 10.5662/wjm.v6.i1.105]
Corresponding Author of This Article
Dr. Pankaj Kumar Garg, Department of Surgery, University College of Medical Sciences and Guru Teg Bahadur Hospital, University of Delhi, Dilshad Garden, Delhi 110095, India. dr.pankajgarg@gmail.com
Research Domain of This Article
Oncology
Article-Type of This Article
Minireviews
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Pankaj Kumar Garg, Department of Surgery, University College of Medical Sciences and Guru Teg Bahadur Hospital, University of Delhi, Delhi 110095, India
Pankaj Kumar Garg, Ashish Jakhetiya, Durgatosh Pandey, Department of Surgical Oncology, Dr BRA Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi 110029, India
Saurabh Kumar Singh, Department of Pulmonary Medicine, Gajra Raja Medical College and Jaya Arogya Group of Hospitals, Gwalior 474009, India
Gaurav Prakash, Clinical Hematology and Bone Marrow Transplant unit, Department of Internal Medicine, Post-Graduate Institute of Medical Education and Research, Chandigarh 160012, India
Author contributions: Garg PK conceptualized the study; Garg PK and Singh SK searched the literature, analyzed the retrieved literature, and wrote the initial draft; Prakash G, Jakhetiya A and Pandey D provided critical inputs in literature search and analysis, and drafting the manuscript; all the authors read the final draft and approved it.
Conflict-of-interest statement: There is no conflict of interest associated with any of the author.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Dr. Pankaj Kumar Garg, Department of Surgery, University College of Medical Sciences and Guru Teg Bahadur Hospital, University of Delhi, Dilshad Garden, Delhi 110095, India. dr.pankajgarg@gmail.com
Telephone: +91-11-22592536 Fax: +91-11-22590495
Received: June 23, 2015 Peer-review started: June 23, 2015 First decision: August 16, 2015 Revised: September 8, 2015 Accepted: February 14, 2016 Article in press: February 16, 2016 Published online: March 26, 2016 Processing time: 269 Days and 9.1 Hours
Abstract
Lung cancer is the leading cause of cancer-related mortality worldwide. Non-small cell carcinoma and small cell carcinoma are the main histological subtypes and constitutes around 85% and 15% of all lung cancer respectively. Multimodality treatment plays a key role in the successful management of lung cancer depending upon the histological subtype, stage of disease, and performance status. Imaging modalities play an important role in the diagnosis and accurate staging of the disease, in assessing the response to neoadjuvant therapy, and in the follow-up of the patients. Last decade has witnessed voluminous upsurge in the use of positron emission tomography-computed tomography (PET-CT); role of PET-CT has widened exponentially in the management of lung cancer. The present article reviews the role of 18-fluoro-deoxyglucose PET-CT in the management of non small cell lung cancer with emphasis on staging of the disease and the assessment of response to neoadjuvant therapy based on available literature.
Core tip: The evidence is evolving for the role of positron emission tomography-computed tomography (PET-CT) in the management of non-small cell lung cancer (NSCLC). Available literature supports the use of PET-CT in the staging of NSCLC to have better disease staging (assessment of mediastinal and extra-thoracic disease). Detection of abnormal mediastinal nodes at various basins is the potential advantage of PET-CT for better targeted biopsy and it may lead to reduction in futile surgical interventions. The role of PET-CT in the prediction and assessment of response to neoadjuvant therapy needs further studies.
